MicroQuin Secures DoD CDMRP Grant to Advance Kidney Cancer Treatment Innovation

Kidney cancer remains a significant health challenge, with thousands of new cases diagnosed annually worldwide. Developing effective treatments is critical to improving patient outcomes. Recently, MicroQuin, a biotechnology company focused on novel cancer therapies, received a grant from the Department of Defense’s Congressionally Directed Medical Research Programs (DoD CDMRP). This funding will support MicroQuin’s efforts to develop new treatments specifically targeting kidney cancer.